DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - NYSE:DOCS - US26622P1075 - Common Stock
72.82 USD
-0.78 (-1.06%)
72.4184 USD
-0.4 (-0.55%)
Overall DOCS gets a fundamental rating of 7 out of 10. We evaluated DOCS against 35 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is valued quite expensively, but it does show have an excellent growth rating. With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
In the past year DOCS had a positive cash flow from operations.
Each year in the past 5 years DOCS has been profitable.
Each year in the past 5 years DOCS had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 19.52%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS has a Return On Equity of 22.93%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
The Return On Invested Capital of DOCS (18.77%) is better than 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.80%.
The last Return On Invested Capital (18.77%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROIC | 18.77% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
DOCS has a better Profit Margin (39.88%) than 100.00% of its industry peers.
In the last couple of years the Profit Margin of DOCS has grown nicely.
Looking at the Operating Margin, with a value of 40.46%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of DOCS has grown nicely.
DOCS's Gross Margin of 90.14% is amongst the best of the industry. DOCS outperforms 97.14% of its industry peers.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
DOCS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 47.91 indicates that DOCS is not in any danger for bankruptcy at the moment.
The Altman-Z score of DOCS (47.91) is better than 100.00% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 47.91 |
ROIC/WACC2
WACC9.4%
2.3 Liquidity
DOCS has a Current Ratio of 6.47. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.47, DOCS belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
A Quick Ratio of 6.47 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a Quick ratio of 6.47. This is amongst the best in the industry. DOCS outperforms 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.27%, which is quite impressive.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
The Revenue has grown by 19.45% in the past year. This is quite good.
The Revenue has been growing by 37.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
Revenue 1Y (TTM)19.45%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
3.2 Future
Based on estimates for the next years, DOCS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.47% on average per year.
The Revenue is expected to grow by 11.87% on average over the next years. This is quite good.
EPS Next Y9.92%
EPS Next 2Y9.06%
EPS Next 3Y11.35%
EPS Next 5Y13.47%
Revenue Next Year12.02%
Revenue Next 2Y11.46%
Revenue Next 3Y11.42%
Revenue Next 5Y11.87%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 48.87, which means the current valuation is very expensive for DOCS.
71.43% of the companies in the same industry are more expensive than DOCS, based on the Price/Earnings ratio.
DOCS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.38.
With a Price/Forward Earnings ratio of 43.42, DOCS can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as DOCS.
DOCS is valuated expensively when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.87 | ||
| Fwd PE | 43.42 |
4.2 Price Multiples
DOCS's Enterprise Value to EBITDA ratio is in line with the industry average.
62.86% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.47 | ||
| EV/EBITDA | 48.48 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.93
PEG (5Y)0.62
EPS Next 2Y9.06%
EPS Next 3Y11.35%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
72.82
-0.78 (-1.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners96.64%
Inst Owner Change-2.61%
Ins Owners1.94%
Ins Owner Change0.09%
Market Cap13.64B
Analysts76.92
Price Target70.49 (-3.2%)
Short Float %3.53%
Short Ratio3.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.11%
Min EPS beat(2)17.55%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)25.17%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.03%
EPS beat(12)12
Avg EPS beat(12)21.73%
EPS beat(16)16
Avg EPS beat(16)33.54%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)1.38%
Max Revenue beat(2)2.52%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.34%
Revenue beat(12)9
Avg Revenue beat(12)2.13%
Revenue beat(16)12
Avg Revenue beat(16)2.76%
PT rev (1m)7.71%
PT rev (3m)12.43%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)10.84%
EPS NY rev (1m)0%
EPS NY rev (3m)16.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.87 | ||
| Fwd PE | 43.42 | ||
| P/S | 23.13 | ||
| P/FCF | 47.47 | ||
| P/OCF | 46.37 | ||
| P/B | 13.3 | ||
| P/tB | 14.58 | ||
| EV/EBITDA | 48.48 |
EPS(TTM)1.49
EY2.05%
EPS(NY)1.68
Fwd EY2.3%
FCF(TTM)1.53
FCFY2.11%
OCF(TTM)1.57
OCFY2.16%
SpS3.15
BVpS5.48
TBVpS5
PEG (NY)4.93
PEG (5Y)0.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROCE | 22.84% | ||
| ROIC | 18.77% | ||
| ROICexc | 96.31% | ||
| ROICexgc | 172.66% | ||
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% | ||
| FCFM | 48.73% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexcg growth 3Y3.35%
ROICexcg growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 62.32% | ||
| Cap/Sales | 1.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.9% | ||
| Profit Quality | 122.2% | ||
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 | ||
| Altman-Z | 47.91 |
F-Score8
WACC9.4%
ROIC/WACC2
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
EPS Next Y9.92%
EPS Next 2Y9.06%
EPS Next 3Y11.35%
EPS Next 5Y13.47%
Revenue 1Y (TTM)19.45%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
Revenue Next Year12.02%
Revenue Next 2Y11.46%
Revenue Next 3Y11.42%
Revenue Next 5Y11.87%
EBIT growth 1Y26.79%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year12.83%
EBIT Next 3Y13.34%
EBIT Next 5Y12.98%
FCF growth 1Y54.23%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y53.19%
OCF growth 3Y29.24%
OCF growth 5Y59.83%